ArticleHormones & cancer2010
Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes.
Article in Hormones & cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- The clinicopathological features and prognosis of silent corticotroph tumors: an updated systematic review and meta-analysis.Endocrine · 2023Pooled it
- Recurrence Rate and Exploration of Clinical Factors after Pituitary Adenoma Surgery: A Systematic Review and Meta-Analysis based on Computer Artificial Intelligence System.Computational intelligence and neuroscience · 2022Pooled it
- Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.Pituitary · 2018Pooled it
- Silent corticotroph adenomas.Pituitary · 2015Pooled it
- GATA3-positive silent corticotroph adenomas are characterized by large size and massive infrasellar invasion.Pituitary · 2026Article
- Corticotroph Tumour Type Influences Clinical Behaviour in Patients With Nonfunctioning Pituitary Neuroendocrine Tumours.Endocrinology, diabetes & metabolism · 2026Article
- Cell Lineage-Specific Differences in Clinical Behavior of Non-Functioning Pituitary Adenomas.The Journal of clinical endocrinology and metabolism · 2025Article
- Phenotype Transformation of PitNETs.Cancers · 2024Review
- A silent corticotroph adenoma: making the case for a pars intermedia origin. Illustrative case.Journal of neurosurgery. Case lessons · 2023Article
- Aggressive nonfunctioning pituitary neuroendocrine tumors.Brain tumor pathology · 2022Review
- Silent Corticotroph and Somatotroph Double Pituitary Adenoma: A Case Report and Review of Literature.Journal of neurological surgery reports · 2022Article
- Pituitary corticotroph tumour with adrenocortical cells: A distinct clinicopathologic entity with unique morphology and methylation profile.Neuropathology and applied neurobiology · 2022Article
- An Update on Silent Corticotroph Adenomas: Diagnosis, Mechanisms, Clinical Features, and Management.Cancers · 2021Review
- DNA methylation-based signatures classify sporadic pituitary tumors according to clinicopathological features.Neuro-oncology · 2021Article
- The silent variants of pituitary tumors: demographic, radiological and molecular characteristics.Journal of endocrinological investigation · 2021Observational
- Article
- Article
- Article
- Predictive modeling for pituitary adenomas: single center experience in 501 consecutive patients.Pituitary · 2019Article
- Predicting early post-operative remission in pituitary adenomas: evaluation of the modified knosp classification.Pituitary · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Silent corticotrophins adenomas (SCAs) are clinically silent and non-secreting but immunostain positively for ACTH. We hypothesize that SCAs comprise both corticotroph and gonadotroph characteristics. Cohort analysis from 1994-2008 with follow-up time ranging from 1-15 years in a tertiary referral center. We compared preoperative and postoperative clinical results and tumor cytogenesis in 25 SCAs and 84 nonfunctioning adenomas in 109 consecutive patients diagnosed pre-operatively with nonfunctioning pituitary adenomas. Clinical outcomes were radiologic and hormonal measures. Pathologic outcomes were expression of relevant pituitary hormones, tissue-specific transcription factors, and electron microscopy features. Preoperative SCA presentation was similar to that observed for nonfunctioning adenomas. However, SCAs recurred postoperatively at a median of 3 years vs. 8 years for nonfunctioning adenomas (p<0.0001). Fifty-four percent of patients with SCAs had new onset postoperative hypopituitarism vs. 17% of nonfunctioning adenomas (p<0.025). SCAs (n=18) were immunopositive for ACTH, cytoplasmic and nuclear SF-1, NeuroD1, DAX-1, and alpha-gonadotropin subunit, but Tpit negative, and co-expression of tumor ACTH with either SF-1 or LH was detected. In contrast, functional corticotroph adenomas (n=11) were immunopositive for ACTH, nuclear SF-1, NeuroD1, and Tpit, but negative for DAX-1, a gonadotroph cell transcription factor. Gonadotroph adenomas (n=23) were immunonegative for ACTH and Tpit but positive for nuclear SF-1, NeuroD1, and DAX-1. SCA electron microscopy demonstrated ultrastructural features consistent with corticotroph and gonadotroph cells. As SCAs exhibit features consistent with both corticotroph and gonadotroph cytologic origin, we propose a pathologic and clinically distinct classification of SCAs as silent corticogonadotroph adenomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.